ResearcherCornell UniversityNo recent work listed
David M. Goldenberg
Matched on ORCID iD 0000-0001-5539-421X; OpenAlex author ID A5003890903. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 29
2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers
Papers 6
- (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
- Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Last author DOI 10.18632/oncotarget.2760↗
- Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Co-author DOI 10.5858/arpa.2013-0056-oa↗
- PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.27762↗
- Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Last author DOI 10.1186/1476-4598-12-143↗
- Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Last author DOI 10.1002/cncr.27592↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David V. Gold · 5 shared papers, 2012–2015 · strength 0.24
- Paper Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for panc… DOI 10.18632/oncotarget.2760↗
- Paper Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. DOI 10.5858/arpa.2013-0056-oa↗
- Paper Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic duc… DOI 10.1186/1476-4598-12-143↗
- Donglin Liu · 2 shared papers, 2013–2015 · strength 0.12
- Paper Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for panc… DOI 10.18632/oncotarget.2760↗
- Paper Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic duc… DOI 10.1186/1476-4598-12-143↗
- William A. Wegener · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- Bert H. O’Neil · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- Allyson J. Ocean · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- Chanjuan Shi · 1 shared paper, 2014 · strength 0.06
- Nipun B. Merchant · 1 shared paper, 2014 · strength 0.06
- Β. Michael Ghadimi · 1 shared paper, 2013 · strength 0.04
- Jochen Gaedcke · 1 shared paper, 2013 · strength 0.04
- Michael Goggins · 1 shared paper, 2013 · strength 0.04
- Ralph H. Hruban MD · 1 shared paper, 2013 · strength 0.04
- Neeta D. Pandit-Taskar · 1 shared paper, 2015 · strength 0.03
- Alexander Starodub · 1 shared paper, 2015 · strength 0.03
- Fa-Chyi Lee · 1 shared paper, 2015 · strength 0.03
- Donald Richards · 1 shared paper, 2015 · strength 0.03
- Eileen Mary O'Reilly · 1 shared paper, 2015 · strength 0.03
- Ronald Lee Korn · 1 shared paper, 2015 · strength 0.03
- Fadi Braiteh · 1 shared paper, 2015 · strength 0.03
- Ramesh K. Ramanathan · 1 shared paper, 2015 · strength 0.03
- Maeve Aine Lowery · 1 shared paper, 2015 · strength 0.03
- Tomislav Dragovich · 1 shared paper, 2015 · strength 0.03
- Richard C. Frank · 1 shared paper, 2015 · strength 0.03
- Nathan Bahary · 1 shared paper, 2015 · strength 0.03
- Vincent J. Picozzi · 1 shared paper, 2015 · strength 0.03
- Steven J. Cohen · 1 shared paper, 2015 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.